

Title (en)
USES OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME

Title (de)
ACYLIERTE AMINOPROPANDIOLE UND IHRE STICKSTOFF- UND SCHWEFEL-ANALOGA ZUR VERSCHIEDENEN THERAPEUTISCHEN ANWENDUNGEN

Title (fr)
AMINOPROPANEDIOLS ACYLES ET LEURS ANALOGUES AZOTES ET SULFURES POUR DIVERSES APPLICATIONS THERAPEUTIQUES

Publication
EP 1594486 A2 20051116 (FR)

Application
EP 04710413 A 20040212

Priority
• FR 2004000320 W 20040212
• FR 0301689 A 20030212

Abstract (en)
[origin: FR2850869A1] The use of acylated aminopropane diols and their analogs (I), their optical and geometric isomers, racemates, salts, and mixtures in pharmaceutical compositions for the treatment of pathological states in which there is lipid or carbohydrate metabolism disturbance, inflammation, and/or cell differentiation or proliferation disturbance. The use of acylated aminopropane diols and their analogs (I), their optical and geometric isomers, racemates, salts, and mixtures in pharmaceutical compositions for the treatment of pathological states in which there is lipid or carbohydrate metabolism disturbance, inflammation, and/or cell differentiation or proliferation disturbance. [Image] G 2, G 3O, S, or N-R4, with the proviso that they are not both N-R4; R, R4 : H, optionally saturated and optionally substituted 1-5C alkyl; R1, R2, R3 : H, CO-R5, or CO-(CH 2) 2n +1-X-R6, at least one of these being CO-(CH 2) 2n+1-X-R6; R5 : optionally saturated and optionally substituted alkyl, that may contain a cyclic group and having 1-25C atoms in the main chain; X : S, Se, SO, or SO 2; n : 0 - 11; R6 : optionally saturated and optionally substituted alkyl, that may contain a cyclic group and one or more hetero groups (O, S, Se, SO or SO 2) and having 3-23C atoms in the main chain. ACTIVITY : Analgesic; Antianginal; Antidiabetic; Antiarteriosclerotic; Anorectic; Antiallergic; Antiasthmatic; Dermatological; Antipsoriatic; Cytostatic. MECHANISM OF ACTION : Peroxisome Proliferator-Activated Receptor activators.

IPC 1-7
A61K 31/131; **A61K 31/133**; **A61K 31/145**; **A61P 3/06**; **A61P 3/08**; **A61P 3/10**; **A61P 29/00**; **A61P 17/00**; **A61P 35/00**

IPC 8 full level
A61K 31/131 (2006.01); **A61K 31/133** (2006.01); **A61K 31/145** (2006.01); **A61P 3/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/08** (2006.01); **A61P 3/10** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 17/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP US)
A61K 31/131 (2013.01 - EP US); **A61K 31/133** (2013.01 - EP US); **A61K 31/145** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/08** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/04** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)
See references of WO 2004073593A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)
AL LT LV MK

DOCDB simple family (publication)
FR 2850869 A1 20040813; **FR 2850869 B1 20050325**; CA 2515480 A1 20040902; EP 1594486 A2 20051116; JP 2006518358 A 20060810; US 2006035977 A1 20060216; WO 2004073593 A2 20040902; WO 2004073593 A3 20041118

DOCDB simple family (application)
FR 0301689 A 20030212; CA 2515480 A 20040212; EP 04710413 A 20040212; FR 2004000320 W 20040212; JP 2006502144 A 20040212; US 54205605 A 20050921